Sarah Sammons, MD, Duke Cancer Institute

The rationale for investigating the role of therapies that target the PI3K pathway in HR+/HER2- metastatic breast cancer.

Sarah Sammons, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

The impact of recent data presented at ESMO 2021 in terms of selecting an appropriate CDK4/6 inhibitor as first-line treatment of HR+/HER2- metastatic breast cancer.

Clinical pearls regarding best practices preventing and/or managing common treatment-related adverse events associated with CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

Dr. Sarah Sammons highlights various first-line treatment approaches that combine CDK4/6 inhibitors with endocrine therapy as treatment for HR+/HER2- metastatic breast cancer.

Reactions to new overall survival results from the MONALEESA-2 study in patients with HR+/HER2- advanced breast cancer in the first-line setting.

A panel of breast oncologists review first-line treatment options for patients with HR+/HER2- metastatic breast cancer, commenting on treatment advances utilizing CKD4/6 inhibitors.

Dr. Neil Iyengar highlights variables that factor into treatment decisions for patients with HR+/HER2- metastatic breast cancer.

Kicking off a discussion regarding recent data presented at ESMO 2021, a panel of breast oncologists share their preferences for conducting molecular testing to identify mutations such as PIK3CA that can help determine how to treat patients with HR+/HER2- metastatic breast cancer.

Sarah Sammons, MD, discusses clinical trials examining lasofoxifene in patients with ESR1-mutant breast cancer.